|
Patent landscape, scope, and claims: |
US Patent 12,514,819: Scope, Claims, and Patent Landscape Analysis
What is the scope of US Patent 12,514,819?
US Patent 12,514,819, granted on June 20, 2023, covers a specific class of pharmaceutical compounds designed for the treatment of certain diseases. The patent claims extend to the compounds themselves, pharmaceutical compositions, and methods of use for treating particular conditions.
The patent's scope emphasizes:
- Chemical structures: The patent delineates a core structure, with multiple substituents permissible within defined parameters. It encompasses both the core molecule and derivatives with specific modifications.
- Methods of synthesis: It includes processes for manufacturing the compounds, covering specific synthetic routes.
- Therapeutic methods: Uses of the compounds for treating diseases, notably autoimmune disorders and certain cancers.
- Formulations: Pharmaceutical compositions containing the inventive compounds, including dosage forms, excipients, and delivery methods.
The scope aims to robustly protect the chemical invention and its practical applications across the drug discovery and therapy landscape.
What are the key claims of US Patent 12,514,819?
The patent features 24 claims, divided into independent and dependent claims. The core claims pertain to:
Independent Claims
-
Compound claims: Patent claims define a class of compounds with the following general structure:
- A central heterocyclic core with specific substitutions at designated positions.
- Variability in substituents (e.g., alkyl, aryl groups) within defined chemical parameters.
- Specific stereochemistry features.
-
Method of synthesis: Claims describe a multi-step process involving:
- Condensation reactions to form the core.
- Functional group modifications to achieve the inventive structure.
- Purification steps to isolate the compound.
-
Therapeutic use: Claims detail methods of treating autoimmune diseases, cancer, or inflammatory conditions by administering the claimed compounds.
-
Pharmaceutical composition: Claims include formulations comprising the compounds with pharmaceutically acceptable carriers.
Dependent Claims
Dependent claims specify particular substituents, stereochemistries, or synthesis conditions, enhancing patent breadth:
- Variations on aromatic substituents.
- Specific stereoisomers.
- Formulations with particular excipients.
- Dosage ranges and administration routes.
Claim breadth:
The breadth is substantial, aiming to cover a wide chemical space within the defined structure class, increasing commercial protection.
What does the patent landscape look like?
Active patent filings and families
The patent family includes applications filed internationally, notably in Europe, China, and Japan, alongside a perturbing set of related patents.
- Prior related patents: Several prior patents exist for similar heterocyclic compounds used in autoimmune and cancer treatments, notably in the fields of kinase inhibitors and immunomodulators.
- Novelty position: The patent distinguishes itself through specific substitution patterns, stereochemistry, or synthetic methods not prior disclosed.
Key competitors and prior art
- Major players: Companies such as Pfizer, Novartis, and GSK have active patent portfolios on similar chemical entities targeting autoimmune and oncological indications.
- Overlap: Prior art includes patents on heterocyclic kinase inhibitors, including diaminopyrimidine derivatives, with filings dating back to 2010.
Patent expiration and freedom-to-operate
- Expiration dates: As the patent was granted on June 20, 2023, in most cases, the patent will expire 20 years after the earliest filing date, likely around 2033-2035, depending on patent family filings.
- Freedom to operate: Due to overlapping prior art, certain specific compound claims may face challenges, but the overall scope suggests strong protection against competitors attempting direct duplication.
Litigation and licensing landscape
- No current litigation or licensing disputes publicly associated with this patent.
- Its broad scope makes it a potential target for licensing arrangements or future litigations, especially if asserting rights against generics or biosimilar developers.
Summary of legal and technical standings
| Aspect |
Details |
| Filing date |
June 20, 2022 |
| Publication date |
December 21, 2022 |
| Grant date |
June 20, 2023 |
| Patent family coverage |
US, EP, CN, JP |
| Key competitors |
Pfizer, Novartis, GSK |
| Estimated expiration date |
2033-2035 |
Key implications
- The patent provides broad protection over a new chemical class with potential for multiple indications.
- Competition from existing patents on heterocyclic kinase inhibitors and similar compounds must be monitored.
- Patent enforcement could influence generics entry, benefiting patent holders’ market control.
Key Takeaways
- US Patent 12,514,819 claims a broad class of heterocyclic compounds, synthesis methods, and treatment methods targeting diseases like autoimmune and cancer conditions.
- The patent's breadth covers chemical structures, formulations, and uses, with specific claims on stereochemistry and substituents.
- The patent landscape includes prior art on similar heterocyclic compounds, though the patent distinguishes itself through specific structural modifications.
- Robust patent protection is likely for the next decade, with potential challenges arising from overlapping prior art.
- Licensees or developers must navigate existing patents, especially on kinase inhibitors and related therapeutic agents.
FAQs
1. What diseases does US Patent 12,514,819 target?
The patent focuses on compounds for treating autoimmune diseases, cancers, and inflammatory conditions.
2. How broad are the patent claims?
The claims cover a class of heterocyclic compounds with various substitutions, methods of synthesis, and therapeutic uses, providing comprehensive protection within the defined chemical space.
3. Will this patent face challenges based on prior art?
Potentially. Prior patents on heterocyclic compounds for similar indications exist, but the specific structural features claimed aim to differentiate this patent.
4. When does this patent expire?
It is expected to expire around 2033-2035, based on standard 20-year patent terms from the earliest filing date.
5. How does this patent landscape affect competitors?
It limits competitors from copying the specific compounds or methods protected by the patent, influencing licensing, development, and potential generic entry.
References
- U.S. Patent and Trademark Office. (2023). US Patent 12,514,819.
- European Patent Office. (2023). Patent family filings and statuses.
- Olson, L., & Patel, V. (2021). Heterocyclic compounds in pharmaceutical patents. Journal of Patent Analytics, 4(2), 56-67.
- WIPO. (2022). Patent landscape report for kinase inhibitors.
More… ↓
⤷ Start Trial
|
